- Conditions
- Hypercholesterolaemia
- Interventions
- Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY), Atorvastatin, Rosuvastatin
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Jacksonville, Florida • Ponte Vedra, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 97
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Hepatitis C
- Interventions
- standard of care, fluvastatin
- Drug
- Lead sponsor
- Bader, Ted, M.D.
- Individual
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Healthy
- Interventions
- Rosuvastatin, Furosemide, MK-2828
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 24 Years to 60 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Coronary Artery Disease
- Interventions
- High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
- Drug · Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 2,476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 80
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
- Conditions
- Healthy Participants
- Interventions
- Digoxin, Divarasib, Rosuvastatin
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Hypercholesterolemia
- Interventions
- Lapaquistat acetate and rosuvastatin, Rosuvastatin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 79 more
- Conditions
- Cystic Fibrosis
- Interventions
- VNZ/TEZ/D-IVA, Rosuvastatin
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Sepsis, Acute Lung Injury
- Interventions
- Rosuvastatin, Placebo
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 745 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 40
- States / cities
- Fresno, California • Sacramento, California • San Francisco, California + 20 more
- Conditions
- Obesity
- Interventions
- PF-06882961, Rosuvastatin, Midazolam
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Breast Cancer
- Interventions
- Rosuvastatin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hypercholesterolemia, Dyslipidemia
- Interventions
- ABT-335 and rosuvastatin calcium, ABT-335, rosuvastatin calcium
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Ozark, Alabama + 135 more
- Conditions
- Advanced Solid Tumor
- Interventions
- Sitravatinib, Warfarin, Dextromethorphan, Midazolam, Digoxin, Rosuvastatin, Nivolumab
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Goshen, Indiana • Austin, Texas • San Antonio, Texas + 2 more
- Conditions
- Dyslipidemia
- Interventions
- AZD0780, Rosuvastatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin
- Drug
- Lead sponsor
- Eccogene
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Venous Thromboembolism, Cancer, Cardiovascular Events
- Interventions
- Rosuvastatin, Placebo Drug
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 9
- States / cities
- Irvine, California • New Haven, Connecticut • Miami, Florida + 4 more
- Conditions
- Advanced Solid Tumors, Metastatic Melanoma
- Interventions
- losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 11
- States / cities
- Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more
- Conditions
- NASH
- Interventions
- Midazolam, Caffeine, Rosuvastatin, EDP-305
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
- Interventions
- Rosuvastatin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 13
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Cardiovascular Complications, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- rosuvastatin, placebo, survey administration, management of therapy complications
- Drug · Other · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Healthy Participants
- Interventions
- AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
- Conditions
- Anaemia
- Interventions
- GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- HIV Infections
- Interventions
- Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Atherosclerosis
- Interventions
- Rosuvastatin 10 mg, Darapladib 160 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 20 Years to 64 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
- Interventions
- Rosuvastatin
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California